QuidelOrtho surges on revenue beat, cash flow turnaround
Diagnostics maker raises free cash flow guidance from loss to $160M on strong Q4 performance
QuidelOrtho shares climbed in Thursday trading after the diagnostic testing company delivered quarterly revenue that topped analyst expectations by 9.1% and dramatically raised its free cash flow guidance for fiscal 2026.
The San Diego-based company reported fourth-quarter revenue of $723.6 million, comfortably ahead of the $663.5 million consensus estimate from Wall Street analysts. The strong performance was driven by growth across the company's diversified diagnostic portfolio, with non-respiratory products advancing 7% and laboratory diagnostics increasing 8%.
Earnings per share of 46 cents narrowly missed the 46.61-cent target, but investors focused instead on the company's upbeat forward guidance. QuidelOrtho projected adjusted EBITDA of $630 million to $670 million for fiscal 2026, representing an operating margin of 23.3%. Most significantly, the company forecasts free cash flow of $120 million to $160 million—a dramatic reversal from the $77 million cash burn expected in fiscal 2025.
The guidance raise marks a pivotal moment for the company, which has been working to expand beyond its COVID-19 testing roots and build sustainable growth in traditional diagnostic categories including cardiology, infectious diseases, and women's health. The turnaround in cash flow projections signals that strategy is beginning to yield operational efficiencies.
QuidelOrtho, which trades under the ticker QDEL on Nasdaq, currently commands a market capitalization of approximately $1.99 billion. The stock, which closed at $28.80 on Thursday, remains well below the average analyst target price of $38.33, suggesting room for upside if the company can deliver on its improved outlook.
Analyst sentiment on the diagnostic maker remains divided, with ratings split between strong buy and buy recommendations versus hold positions. One analyst maintains a strong sell rating, reflecting ongoing concerns about the competitive landscape in the diagnostics industry.
The company's forward price-to-earnings ratio of 11.06 suggests the shares trade at a modest valuation relative to growth expectations, particularly given the improved free cash flow profile. The stock has recovered from its 52-week low of $19.50 but remains well below the $43.92 peak reached over the past year.
QuidelOrtho's ability to grow its non-respiratory and laboratory segments by 7% and 8% respectively demonstrates progress in diversifying revenue streams beyond pandemic-related testing, which had driven volatile swings in performance during the height of COVID-19. The company's diagnostic portfolio spans rapid testing platforms and sophisticated laboratory equipment, positioning it across multiple points of care.
Investors will be watching closely in coming quarters for evidence that the free cash flow guidance is achievable and whether the operational improvements driving the stronger outlook can be sustained. The diagnostic industry faces ongoing pressure from healthcare cost containment measures and intense competition from larger players including Abbott Laboratories and Roche.